Status:

COMPLETED

Assessing the Effect of Nicotine Reduction on ENDS User's Addiction and Exposures

Lead Sponsor:

Florida International University

Conditions:

Electronic Cigarette Use

Eligibility:

All Genders

21-35 years

Phase:

NA

Brief Summary

The rapid increase of electronic nicotine delivery systems (ENDS) use by young people in the US and their potential to harm health, cause addiction, and serve as a risk for cigarette smoking or dual-u...

Detailed Description

The use of electronic nicotine delivery systems (ENDS or e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS emit toxic substances, including nicotine that irr...

Eligibility Criteria

Inclusion

  • Generally healthy individuals (determined by physical examination).
  • Age of 21-35 years.
  • Is willing to provide informed consent.
  • Is willing to attend the lab as required by the study protocol.
  • Electronic cigarette users (defined as using electronic cigarette either daily or occasionally in the past 30 days)
  • Have abstained from electronic cigarette use for 12 hours prior to each session

Exclusion

  • Report smoking cigarettes regularly (\> 5 cigarettes/month in the past year).
  • Report regular use of any other tobacco/nicotine product (e.g.,hookah, pipes, cigars) in the past year.
  • Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).
  • Individuals with self-reported history of chronic disease or current psychiatric conditions.
  • Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).
  • Individuals that report current THC (marijuana) smoking/vaping.
  • Individuals that report the use of non-commercial (i.e., street) e-cigarette liquid or products
  • Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)
  • Individuals that have or have been exposed to COVID-19 in the last 14 days.

Key Trial Info

Start Date :

April 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 15 2025

Estimated Enrollment :

116 Patients enrolled

Trial Details

Trial ID

NCT05205382

Start Date

April 1 2022

End Date

April 15 2025

Last Update

September 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Florida International University

Miami, Florida, United States, 33199